Prosecution Insights
Last updated: April 19, 2026
Application No. 18/010,587

COMPOSITION FOR HAIR GROWTH AND/OR HAIR RESTORATION

Non-Final OA §102§103
Filed
Dec 15, 2022
Examiner
YU, HONG
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Institute Of Rheological Function Of Food Co. Ltd.
OA Round
3 (Non-Final)
31%
Grant Probability
At Risk
3-4
OA Rounds
4y 0m
To Grant
37%
With Interview

Examiner Intelligence

Grants only 31% of cases
31%
Career Allow Rate
214 granted / 681 resolved
-28.6% vs TC avg
Moderate +5% lift
Without
With
+5.3%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
73 currently pending
Career history
754
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
49.5%
+9.5% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
15.1%
-24.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 681 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/09/2026 has been entered. Status of claims The amendment filed on 01/09/2026 is acknowledged. Claims 1 and 2 have been canceled. Claims 3 and 4 are under examination in the instant office action. Rejections withdrawn Applicant’s amendments and arguments filed on 01/09/2026 are acknowledged and have been fully considered. Any rejection and/or objection not specifically addressed below is herein withdrawn. Applicant’s amendments have overcome the 35 U.S.C. 102(a)(1) rejections of claims 3 and 4 over Mawatari et al. (US 2013/0172293 A1) and of claims 3 and 4 over Forgeot (US 5,759,585) from the previous Office Action. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application. New ground of rejections necessitated by Applicant’s amendment The amendments necessitate the following new ground of rejections. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim 3 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pierard (US 6,482,826 B1). Pierard meets all of the limitations of claim 3. Pierard discloses a method of treating individuals with alopecia for reversing alopecia (the claimed hair growth and/or hair restoration) (column 4, line 52-56) by administering to the scalp of said individuals an effective amount of ketoconazole as active ingredient (abstract) with the active ingredient being formulated in liposome-containing compositions; wherein the liposomes are formed with plasmalogens (column 3, line 36-44). Claims 3 and 4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Seigfried (US 2011/0059117 A1). Seigfried meets all of the limitations of claims 3 and 4. Seigfried discloses a method of treating hair loss comprising topical application, to the skin of a warm-blooded mammal in need thereof of, a liquid composition comprising a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent (claims 10 and 54); wherein the skin includes scalp (paragraph 70); and wherein the phospholipid foaming agents include choline plasmalogen of animal origin (the claimed animal tissue in the instant claim 4) (paragraph 33 and 34). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 3 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pierard (US6,482,826 B1) in view of Mawatari et al. (US 2013/0172293 A1). The teachings of Pierard are discussed above and applied in the same manner. Pierard do not specify the source of plasmalogen in the instant claim 4. This deficiency is cured by Mawatari et al. who teach plasmalogen extracted from avian tissue (the claimed animal tissue in the instant claim 4) (abstract). It would have been prima facie obvious before the effective filing date of the claimed invention to a person of ordinary skill in the art to combine the teachings in Pierard and Mawatari et al. to specify plasmalogen taught by Pierard being avian tissue extraction. Plasmalogen being avian tissue extraction tissue was well known to a person of ordinary skill in the art before the effective filing date of the claimed invention. The motivation for specifying it flows from its having been used in the prior art, and from its being recognized in the prior art as useful for the same purpose. Response to Applicants’ arguments: Applicant’s arguments, filed on 01/09/2026, have been fully considered but they are moot in view of new ground of rejections. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to HONG YU whose telephone number is (571)270-1328. The examiner can normally be reached on 9 am - 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached on 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HONG YU/ Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Dec 15, 2022
Application Filed
Apr 23, 2025
Non-Final Rejection — §102, §103
Jul 23, 2025
Response Filed
Oct 23, 2025
Final Rejection — §102, §103
Nov 26, 2025
Response after Non-Final Action
Jan 09, 2026
Request for Continued Examination
Jan 13, 2026
Response after Non-Final Action
Feb 06, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599623
SKIN COMPOSITIONS AND METHODS OF USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12589059
MINERAL SUNSCREEN COMPOSITIONS WITH HIGH SPF AND SHELF STABILITY
2y 5m to grant Granted Mar 31, 2026
Patent 12577725
ODOR CONTROL COMPOSITION AND METHOD OF USING
2y 5m to grant Granted Mar 17, 2026
Patent 12569428
OIL-IN-WATER CLEANSING COSMETIC COMPOSITION
2y 5m to grant Granted Mar 10, 2026
Patent 12558432
BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
31%
Grant Probability
37%
With Interview (+5.3%)
4y 0m
Median Time to Grant
High
PTA Risk
Based on 681 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month